Skip to main content
Top
Published in: Breast Cancer Research 1/2022

01-12-2022 | Breast Cancer | Research article

Assessing lead time bias due to mammography screening on estimates of loss in life expectancy

Authors: Elisavet Syriopoulou, Alessandro Gasparini, Keith Humphreys, Therese M.-L. Andersson

Published in: Breast Cancer Research | Issue 1/2022

Login to get access

Abstract

Background

An increasingly popular measure for summarising cancer prognosis is the loss in life expectancy (LLE), i.e. the reduction in life expectancy following a cancer diagnosis. The proportion of life lost (PLL) can also be derived, improving comparability across age groups as LLE is highly age-dependent. LLE and PLL are often used to assess the impact of cancer over the remaining lifespan and across groups (e.g. socioeconomic groups). However, in the presence of screening, it is unclear whether part of the differences across population groups could be attributed to lead time bias. Lead time is the extra time added due to early diagnosis, that is, the time from tumour detection through screening to the time that cancer would have been diagnosed symptomatically. It leads to artificially inflated survival estimates even when there are no real survival improvements.

Methods

In this paper, we used a simulation-based approach to assess the impact of lead time due to mammography screening on the estimation of LLE and PLL in breast cancer patients. A natural history model developed in a Swedish setting was used to simulate the growth of breast cancer tumours and age at symptomatic detection. Then, a screening programme similar to current guidelines in Sweden was imposed, with individuals aged 40–74 invited to participate every second year; different scenarios were considered for screening sensitivity and attendance. To isolate the lead time bias of screening, we assumed that screening does not affect the actual time of death. Finally, estimates of LLE and PLL were obtained in the absence and presence of screening, and their difference was used to derive the lead time bias.

Results

The largest absolute bias for LLE was 0.61 years for a high screening sensitivity scenario and assuming perfect screening attendance. The absolute bias was reduced to 0.46 years when the perfect attendance assumption was relaxed to allow for imperfect attendance across screening visits. Bias was also present for the PLL estimates.

Conclusions

The results of the analysis suggested that lead time bias influences LLE and PLL metrics, thus requiring special consideration when interpreting comparisons across calendar time or population groups.
Appendix
Available only for authorised users
Literature
2.
go back to reference Andersson TM-L, Dickman PW, Eloranta S, Lambe M, Lambert PC. Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Stat Med. 2013;32:5286–300.CrossRef Andersson TM-L, Dickman PW, Eloranta S, Lambe M, Lambert PC. Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Stat Med. 2013;32:5286–300.CrossRef
6.
go back to reference Ekberg S, Jerkeman M, Andersson PO, Enblad G, Wahlin BE, Hasselblom S, Andersson TM-L, Eloranta S, Smedby KE. Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large b-cell lymphoma. Am J Hematol. 2018;93:1020–8. https://doi.org/10.1002/ajh.25147.CrossRef Ekberg S, Jerkeman M, Andersson PO, Enblad G, Wahlin BE, Hasselblom S, Andersson TM-L, Eloranta S, Smedby KE. Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large b-cell lymphoma. Am J Hematol. 2018;93:1020–8. https://​doi.​org/​10.​1002/​ajh.​25147.CrossRef
7.
go back to reference Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778–86. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778–86.
12.
21.
go back to reference von Wagner C, Baio G, Raine R, Snowball J, Morris S, Atkin W, Obichere A, Handley G, Logan RF, Rainbow S, Smith S, Halloran S, Wardle J. Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. Int J Epidemiol. 2011;40:712–8. https://doi.org/10.1093/ije/dyr008.CrossRef von Wagner C, Baio G, Raine R, Snowball J, Morris S, Atkin W, Obichere A, Handley G, Logan RF, Rainbow S, Smith S, Halloran S, Wardle J. Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. Int J Epidemiol. 2011;40:712–8. https://​doi.​org/​10.​1093/​ije/​dyr008.CrossRef
29.
go back to reference Royston P, Lambert P. Flexible parametric survival analysis in stata: beyond the cox model. College Station: Stata Press; 2011. Royston P, Lambert P. Flexible parametric survival analysis in stata: beyond the cox model. College Station: Stata Press; 2011.
32.
go back to reference Statistics Sweden (Statistiska Centralbyrån): The future population of Sweden 2012–2060. Technical report, Demographic reports. 2012. Statistics Sweden (Statistiska Centralbyrån): The future population of Sweden 2012–2060. Technical report, Demographic reports. 2012.
34.
go back to reference Magnusson C, Baron J, Persson I, Wolk A, Bergström R, Trichopoulos D, Adami HO. Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer. 1998;76(1):29–34.CrossRef Magnusson C, Baron J, Persson I, Wolk A, Bergström R, Trichopoulos D, Adami HO. Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer. 1998;76(1):29–34.CrossRef
42.
go back to reference Fournier DV, Weber E, Hoeffken W, Bauer M, Kubli F, Barth V. Growth rate of 147 mammary carcinomas. Cancer. 1980;45:2198–207.CrossRef Fournier DV, Weber E, Hoeffken W, Bauer M, Kubli F, Barth V. Growth rate of 147 mammary carcinomas. Cancer. 1980;45:2198–207.CrossRef
Metadata
Title
Assessing lead time bias due to mammography screening on estimates of loss in life expectancy
Authors
Elisavet Syriopoulou
Alessandro Gasparini
Keith Humphreys
Therese M.-L. Andersson
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2022
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-022-01505-3

Other articles of this Issue 1/2022

Breast Cancer Research 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine